Acadia Pharmaceuticals Inc (ACAD) Institutional Ownership

Ownership Summary

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 325 institutional investors with active 13F positions as of December 2025.

• They owned 97.1% of outstanding stock in December 2025, down from 99.0% the prior quarter.
• Their total shares held in ACAD increased 0.41% from the prior quarter, while the number of investors in Acadia Pharmaceuticals increased 10.92% year over year.
• During the quarter, 169 of these 325 funds increased positions in ACAD, 114 reduced exposure, and 42 held steady.
• In total, institutional investors held 165.7Mn shares in Acadia Pharmaceuticals as of December 2025, up by 680.29K shares quarter on quarter, and down 6.57Mn shares year over year.
• BAKER BROS. ADVISORS LP holds the largest position in ACAD at 42.9Mn shares as of December 31, 2025, or 25.14% of shares outstanding.
• The largest buyers of Acadia Pharmaceuticals for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (8.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.66Mn), Artisan Partners Limited Partnership (1.33Mn), FIRST TRUST ADVISORS LP (1.07Mn), VANGUARD FIDUCIARY TRUST CO (875.72K).
• Top sellers of ACAD stock for the quarter ending December 2025 included Goldman Sachs Group Inc (1.58Mn), Rockefeller Capital Management L.P. (1.2Mn), Point72 Asset Management, L.P. (799.4K), EMERALD ADVISERS, LLC (782.56K), CITADEL ADVISORS LLC (744.7K).
• Per Business Quant, the top 10 investors in ACAD for the quarter ending December 2025 include BAKER BROS. ADVISORS LP (42.9Mn), BlackRock, Inc. (21.55Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (8.67Mn), State Street Corp (8.33Mn), RTW INVESTMENTS, LP (7.14Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.66Mn), GEODE CAPITAL MANAGEMENT, LLC (3.46Mn), FIRST TRUST ADVISORS LP (3.34Mn), DIMENSIONAL FUND ADVISORS LP (3.16Mn), Palo Alto Investors LP (2.87Mn).